Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04250246
Title A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Italian Network for Tumor Biotherapy Foundation


lung non-small cell carcinoma


Ipilimumab + Nivolumab

Guadecitabine + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST